Hospital
Agh Mesa LLC
Agh Mesa LLC was paid $28.01M by Medicaid between Dec 2018 and Dec 2024, across 201 billing codes. Its largest line is 99284, emergency room visit (serious) — 30% of everything it billed.
33Billing provider infoAGH MESA LLC
MESA, AZ 85212
MESA, AZ 85212
33aNPI1689121188assigned 09/01/2016
33bProvider typeGeneral Acute Care Hospital
28Total paid$28.01M
24GClaims553,129
24DCodes billed201
24AFirst – last monthDec 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arizona
Rank by total paid#19 of 78
Median peer was paid$12.21M
This provider vs. median2.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HANSON, JANE controls 19+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 97 | $3K | |
| 2019 | 41,952 | $2.02M | |
| 2020 | 85,197 | $4.82M | |
| 2021 | 182,061 | $10.32M | |
| 2022 | 148,906 | $7.69M | |
| 2023 | 53,790 | $1.73M | |
| 2024incomplete | 41,126 | $1.42M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 30% | 35,450 | 32,840 | $8.40M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 25% | 43,620 | 40,957 | $7.06M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 23% | 22,634 | 20,384 | $6.39M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 9.7% | 5,437 | 5,062 | $2.72M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.2% | 8,983 | 8,631 | $905K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.9% | 4,076 | 3,772 | $811K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.7% | 1,182 | 1,083 | $477K |
| G0378 | Hospital observation service, per hour | 1.1% | 4,084 | 2,300 | $302K |
| 44970 | <1% | 61 | 54 | $181K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 222 | 212 | $174K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 4,593 | 4,323 | $171K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 828 | 795 | $164K |
189 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 7,651 | $76K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 968 | $49K |
| 80053 | Comprehensive metabolic panel | <1% | 32,755 | $13K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,029 | $13K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 11,512 | $12K |
| 72131 | <1% | 194 | $11K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 15,942 | $11K |
| 10060 | <1% | 536 | $8K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,805 | $7K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,564 | $5K |
| 96376 | <1% | 4,675 | $5K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 13,234 | $5K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,725 | $3K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,400 | $3K |
| 71045 | Radiologic examination, chest; single view | <1% | 11,877 | $3K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 32,986 | $2K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,322 | $2K |
| J3490 | Unclassified drugs | <1% | 7,753 | $2K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 47 | $2K |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 486 | $2K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 11,288 | $2K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,169 | $1K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 5,357 | $1K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 5,452 | $1K |
| 71250 | <1% | 264 | $1K | |
| 73562 | <1% | 1,527 | $1K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,192 | $1K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,048 | $1K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 862 | $938.17 |
| 93976 | <1% | 839 | $914.46 | |
| 96367 | <1% | 420 | $892.55 | |
| 84703 | <1% | 6,109 | $779.59 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 703 | $692.03 |
| 12011 | <1% | 463 | $667.78 | |
| 70486 | <1% | 274 | $650.32 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 5,428 | $624.80 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 874 | $603.45 |
| 83880 | <1% | 1,648 | $600.66 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 13,309 | $553.81 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 3,620 | $471.87 |
| A9270 | Non-covered item or service | <1% | 14,988 | $458.38 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,479 | $450.77 |
| 81025 | <1% | 6,204 | $442.57 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,431 | $377.22 |
| 81003 | <1% | 17,961 | $372.51 | |
| 84484 | <1% | 7,806 | $358.52 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,349 | $323.26 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 56 | $323.19 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 14,608 | $321.50 |
| 82150 | <1% | 2,756 | $266.47 | |
| 80306 | <1% | 2,105 | $246.97 | |
| 87631 | <1% | 88 | $245.60 | |
| 73610 | <1% | 1,571 | $226.31 | |
| 83605 | <1% | 3,799 | $214.47 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 6,672 | $211.43 |
| 36415 | Collection of venous blood by venipuncture | <1% | 11,218 | $203.45 |
| 72100 | <1% | 473 | $189.66 | |
| 82962 | <1% | 1,477 | $181.85 | |
| 73030 | <1% | 936 | $179.00 | |
| 88304 | <1% | 503 | $177.85 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,703 | $168.01 |
| 83735 | <1% | 3,435 | $167.05 | |
| 73630 | <1% | 2,060 | $163.03 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,550 | $150.07 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 894 | $147.14 |
| 76801 | <1% | 593 | $143.26 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 991 | $123.61 |
| 73130 | <1% | 1,500 | $108.18 | |
| 84702 | <1% | 2,114 | $107.87 | |
| 93971 | <1% | 800 | $104.15 | |
| 90715 | <1% | 1,270 | $97.35 | |
| 73110 | <1% | 1,011 | $97.26 | |
| 82550 | <1% | 1,314 | $89.00 | |
| 74018 | <1% | 831 | $84.34 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,673 | $78.21 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,297 | $77.99 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,417 | $77.84 |
| 29125 | <1% | 368 | $75.84 | |
| 83690 | <1% | 4,291 | $68.75 | |
| 73140 | <1% | 614 | $65.58 | |
| 85379 | <1% | 2,994 | $60.47 | |
| 76830 | Ultrasound, transvaginal | <1% | 413 | $60.00 |
| 12001 | <1% | 752 | $56.45 | |
| 85027 | <1% | 1,407 | $54.47 | |
| 12002 | <1% | 134 | $52.82 | |
| 85610 | <1% | 2,848 | $51.65 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 69 | $51.31 |
| 81001 | <1% | 2,862 | $45.32 | |
| 73080 | <1% | 480 | $37.27 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,004 | $36.13 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,019 | $32.99 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 242 | $32.40 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,371 | $32.12 |
| 74019 | <1% | 177 | $30.10 | |
| 72040 | <1% | 174 | $25.98 | |
| 82803 | <1% | 352 | $20.79 | |
| 82553 | <1% | 257 | $20.26 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 514 | $19.77 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,118 | $16.03 |
| J2704 | Injection, propofol, 10 mg | <1% | 1,217 | $15.82 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,052 | $15.72 |
| 82565 | <1% | 594 | $14.32 | |
| 84132 | <1% | 586 | $13.12 | |
| 87077 | <1% | 326 | $12.92 | |
| 93975 | <1% | 60 | $11.94 | |
| 82947 | <1% | 1,030 | $11.69 | |
| 84520 | <1% | 594 | $11.59 | |
| 73590 | <1% | 319 | $10.00 | |
| 82374 | <1% | 536 | $9.79 | |
| 84295 | <1% | 551 | $9.73 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 692 | $9.65 |
| 82435 | <1% | 551 | $9.54 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 501 | $9.20 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 198 | $7.18 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,015 | $6.97 |
| 87186 | <1% | 244 | $6.92 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 765 | $6.41 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 141 | $6.00 |
| 85007 | <1% | 646 | $5.42 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,257 | $3.45 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 286 | $1.24 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 282 | $0.79 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 96 | $0.24 |
| 86308 | 0% | 53 | $0.00 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 52 | $0.00 |
| 87510 | 0% | 399 | $0.00 | |
| 87070 | 0% | 399 | $0.00 | |
| 87040 | 0% | 2,253 | $0.00 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 0% | 234 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 342 | $0.00 |
| 80329 | 0% | 234 | $0.00 | |
| 80320 | 0% | 600 | $0.00 | |
| 73090 | 0% | 381 | $0.00 | |
| 83036 | Hemoglobin; glycosylated (A1C) | 0% | 318 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 344 | $0.00 |
| 71101 | 0% | 211 | $0.00 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 210 | $0.00 |
| 29130 | 0% | 68 | $0.00 | |
| 85730 | 0% | 486 | $0.00 | |
| 72072 | 0% | 36 | $0.00 | |
| 73660 | 0% | 113 | $0.00 | |
| 86901 | 0% | 202 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 349 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 51 | $0.00 |
| 80051 | 0% | 12 | $0.00 | |
| 73502 | 0% | 180 | $0.00 | |
| J0456 | Injection, azithromycin, 500 mg | 0% | 37 | $0.00 |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 0% | 97 | $0.00 |
| 86140 | 0% | 123 | $0.00 | |
| 87480 | 0% | 400 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 53 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 13 | $0.00 |
| 87428 | 0% | 54 | $0.00 | |
| 76870 | 0% | 44 | $0.00 | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | 0% | 28 | $0.00 |
| J1836 | Injection, metronidazole, 10 mg | 0% | 55 | $0.00 |
| 64400 | 0% | 12 | $0.00 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 0% | 75 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 22 | $0.00 |
| 73564 | 0% | 14 | $0.00 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 15 | $0.00 |
| 96368 | 0% | 30 | $0.00 | |
| 74021 | 0% | 12 | $0.00 | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 0% | 13 | $0.00 |
| 94760 | 0% | 17 | $0.00 | |
| 73060 | 0% | 26 | $0.00 | |
| 73552 | 0% | 12 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 466 | $0.00 |
| 87660 | 0% | 399 | $0.00 | |
| 84145 | 0% | 110 | $0.00 | |
| 80061 | Lipid panel | 0% | 52 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 689 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 156 | $0.00 |
| 80076 | 0% | 55 | $0.00 | |
| 29530 | 0% | 113 | $0.00 | |
| 87634 | 0% | 429 | $0.00 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 20 | $0.00 |
| 84100 | 0% | 104 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 12 | $0.00 |
| 86900 | 0% | 130 | $0.00 | |
| 82248 | 0% | 35 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 14 | $0.00 |
| 29105 | 0% | 14 | $0.00 | |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | 0% | 93 | $0.00 |
| 29515 | 0% | 13 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 65 | $0.00 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 16 | $0.00 |
| 93970 | 0% | 41 | $0.00 | |
| 69209 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHANSON, JANE (PRESIDENT/CEO)
| Provider | Location | Paid |
|---|---|---|
| Agh Laveen LLC | Laveen, AZ | $109.33M |
| Agh Laveen LLC | Glendale, AZ | $14.88M |
| Agh Mesa LLC | Mesa, AZ | $4.69M |
| Agh Laveen LLC | Goodyear, AZ | $4.04M |
| Agh Laveen LLC | Surprise, AZ | $3.48M |
| Agh Laveen LLC | Glendale, AZ | $3.40M |
| Agh Mesa LLC | Tempe, AZ | $3.34M |
| Agh Mesa LLC | Chandler, AZ | $2.76M |
| Agh Mesa LLC | Mesa, AZ | $2.66M |
| Agh Mesa LLC | San Tan Valley, AZ | $2.32M |
| Agh Mesa LLC | Phoenix, AZ | $1.74M |
| Agh Mesa LLC | Chandler, AZ | $1.12M |
| Agh Mesa LLC | Gilbert, AZ | $978K |
| Agh Laveen LLC | Mesa, AZ | $293K |
| Agh Laveen LLC | Chandler, AZ | $259K |
| Agh Laveen LLC | Phoenix, AZ | $184K |
| Agh Laveen LLC | Mesa, AZ | $167K |
| Agh Laveen LLC | Gilbert, AZ | $160K |
| Agh Laveen LLC | Chandler, AZ | $41K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.